Kalvista Pharmaceuticals Inc (KALV) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Kalvista Pharmaceuticals Inc

NASDAQ | KALV

11.32

USD

+0.23 (+2.07%)

AT CLOSE (AS OF Apr 3, 2025)

$551M

MARKET CAP

P/E Ratio

-3.77

EPS

$16

52 Week High

$7.3

52 Week Low

LIFE SCIENCES

Sector

KALV Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

KALV Technicals

Tags:

KALV Earnings

Yearly Income Statement (As of Apr 30, 2024)

Field	Value (USD)
Gross Profit	-$53M
Total Revenue	$1.4M
Cost Of Revenue	$54M
Costof Goods And Services Sold	$86M
Operating Income	-$140M
Selling General And Administrative	$54M
Research And Development	$86M
Operating Expenses	$140M
Investment Income Net	$3.9M
Net Interest Income	$3.9M
Interest Income	$3.9M
Interest Expense	$92K
Non Interest Income	$1.4M
Other Non Operating Income	$9.8M
Depreciation	-
Depreciation And Amortization	$816K
Income Before Tax	-$127M
Income Tax Expense	$0
Interest And Debt Expense	$92K
Net Income From Continuing Operations	-$127M
Comprehensive Income Net Of Tax	-$127M
Ebit	-$140M
Ebitda	-$134M
Net Income	-$127M

Revenue & Profitability

Earnings Performance

KALV Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Apr 30, 2024)

Field	Value (USD)
Total Assets	$235M
Total Current Assets	$226M
Cash And Cash Equivalents At Carrying Value	$32M
Cash And Short Term Investments	$210M
Inventory	-
Current Net Receivables	$1M
Total Non Current Assets	$9.7M
Property Plant Equipment	$2.2M
Accumulated Depreciation Amortization Ppe	$3.7M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$179M
Long Term Investments	-
Short Term Investments	$179M
Other Current Assets	$4.4M
Other Non Current Assets	$567K
Total Liabilities	$29M
Total Current Liabilities	$23M
Current Accounts Payable	$9.1M
Deferred Revenue	-
Current Debt	-
Short Term Debt	$1.3M
Total Non Current Liabilities	$6M
Capital Lease Obligations	$7.3M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$7.3M
Other Current Liabilities	$12M
Other Non Current Liabilities	-
Total Shareholder Equity	$207M
Treasury Stock	-
Retained Earnings	-$470M
Common Stock	$42K
Common Stock Shares Outstanding	$43M

yearly Cash Flow (As of Apr 30, 2024)

Field	Value (USD)
Operating Cashflow	-$89M
Payments For Operating Activities	$1.7M
Proceeds From Operating Activities	-
Change In Operating Liabilities	$7.5M
Change In Operating Assets	$538K
Depreciation Depletion And Amortization	$816K
Capital Expenditures	$443K
Change In Receivables	-
Change In Inventory	-
Profit Loss	-$127M
Cashflow From Investment	-$85M
Cashflow From Financing	$151M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$97M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	$53M
Proceeds From Repurchase Of Equity	$151M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$127M

yearly Income Statement (As of Apr 30, 2024)

Field	Value (USD)
Gross Profit	-$53M
Total Revenue	$1.4M
Cost Of Revenue	$54M
Costof Goods And Services Sold	$86M
Operating Income	-$140M
Selling General And Administrative	$54M
Research And Development	$86M
Operating Expenses	$140M
Investment Income Net	$3.9M
Net Interest Income	$3.9M
Interest Income	$3.9M
Interest Expense	$92K
Non Interest Income	$1.4M
Other Non Operating Income	$9.8M
Depreciation	-
Depreciation And Amortization	$816K
Income Before Tax	-$127M
Income Tax Expense	$0
Interest And Debt Expense	$92K
Net Income From Continuing Operations	-$127M
Comprehensive Income Net Of Tax	-$127M
Ebit	-$140M
Ebitda	-$134M
Net Income	-$127M

KALV Profile

Kalvista Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.42	84.14%	$4.04M	177,332,811

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.42	84.14%	$4.04M	177,332,811
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

KALV $11.32 (+2.07%) Quote details